1 Executive Summary 2 Preface 2.1 Abstract 2.2 Stake Holders 2.3 Research Scope 2.4 Research Methodology 2.4.1 Data Mining 2.4.2 Data Analysis 2.4.3 Data Validation 2.4.4 Research Approach 2.5 Research Sources 2.5.1 Primary Research Sources 2.5.2 Secondary Research Sources 2.5.3 Assumptions 3 Market Trend Analysis 3.1 Introduction 3.2 Drivers 3.3 Restraints 3.4 Opportunities 3.5 Threats 3.6 End User Analysis 3.7 Emerging Markets 3.8 Futuristic Market Scenario 4 Porters Five Force Analysis 4.1 Bargaining power of suppliers 4.2 Bargaining power of buyers 4.3 Threat of substitutes 4.4 Threat of new entrants 4.5 Competitive rivalry 5 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, By Type 5.1 Introduction 5.2 Hepatic fibrosis biomarkers 5.3 Serum biomarkers 5.4 Oxidative stress biomarkers 5.5 Apoptosis biomarkers 5.5 Other Biomarkers Types 6 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, By End-user 6.1 Introduction 6.2 Hospitals 6.3 Pharma & CRO Industry 6.4 Academic Research Institutes 6.5 Diagnostic Labs 7 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, By Geography 7.1 Introduction 7.2 North America 7.2.1 US 7.2.2 Canada 7.2.3 Mexico 7.3 Europe 7.3.1 Germany 7.3.2 U.K 7.3.3 France 7.3.4 Italy 7.3.5 Spain 7.3.6 Rest of Europe 7.4 Asia Pacific 7.4.1 Japan 7.4.2 China 7.4.3 India 7.4.4 Australia 7.4.5 New Zealand 7.4.6 South Korea 7.4.7 Rest of Asia Pacific 7.5 South America 7.5.1 Argentina 7.5.2 Brazil 7.5.3 Chile 7.5.4 Rest of South America 7.6 Middle East & Africa 7.6.1 Saudi Arabia 7.6.2 UAE 7.6.3 Qatar 7.6.4 South Africa 7.6.5 Rest of Global 8 Key Developments 8.1 Agreements, Partnerships, Collaborations and Joint Ventures 8.2 Acquisitions & Mergers 8.3 New Product Launch 8.4 Expansions 8.5 Other Key Strategies 9 Company Profiling 9.1 Allergan Plc 9.2 AstraZeneca 9.3 Boehringer Ingelheim 9.4 Bristol-Myers Squibb Company 9.5 Dainippon Sumitomo Pharma (DSP) 9.6 Enzo Biochem 9.7 GENFIT SA 9.8 Gilead Sciences, Inc. (GILD) 9.9 Intercept Pharmaceuticals 9.10 Novartis AG 9.11 Novo Nordisk A/S 9.12 Pfizer Inc 9.13 Prometheus Laboratories Corp 9.14 Raptor Pharmaceutical Corp 9.15 Siemens Heathcare Pvt. Ltd. List of Tables Table 1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Region (2014-2023) ($MN) Table 2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN) Table 3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN) Table 4 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN) Table 5 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN) Table 6 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN) Table 7 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN) Table 8 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN) Table 9 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN) Table 10 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN) Table 11 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN) Table 12 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN) Table 13 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Country (2014-2023) ($MN) Table 14 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN) Table 15 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN) Table 16 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN) Table 17 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN) Table 18 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN) Table 19 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN) Table 20 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN) Table 21 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN) Table 22 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN) Table 23 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN) Table 24 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN) Table 25 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Country (2014-2023) ($MN) Table 26 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN) Table 27 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN) Table 28 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN) Table 29 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN) Table 30 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN) Table 31 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN) Table 32 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN) Table 33 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN) Table 34 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN) Table 35 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN) Table 36 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN) Table 37 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Country (2014-2023) ($MN) Table 38 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN) Table 39 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN) Table 40 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN) Table 41 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN) Table 42 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN) Table 43 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN) Table 44 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN) Table 45 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN) Table 46 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN) Table 47 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN) Table 48 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN) Table 49 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Country (2014-2023) ($MN) Table 50 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN) Table 51 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN) Table 52 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN) Table 53 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN) Table 54 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN) Table 55 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN) Table 56 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN) Table 57 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN) Table 58 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN) Table 59 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN) Table 60 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN) Table 61 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Country (2014-2023) ($MN) Table 62 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Type (2014-2023) ($MN) Table 63 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hepatic fibrosis biomarkers (2014-2023) ($MN) Table 64 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Serum biomarkers (2014-2023) ($MN) Table 65 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Oxidative stress biomarkers (2014-2023) ($MN) Table 66 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Apoptosis biomarkers (2014-2023) ($MN) Table 67 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Other Biomarkers Types (2014-2023) ($MN) Table 68 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By End-user (2014-2023) ($MN) Table 69 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Hospitals (2014-2023) ($MN) Table 70 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Pharma & CRO Industry (2014-2023) ($MN) Table 71 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Academic Research Institutes (2014-2023) ($MN) Table 72 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook, By Diagnostic Labs (2014-2023) ($MN)